| Literature DB >> 25500077 |
Ninna Aggerholm-Pedersen1, Akmal Safwat2, Steen Bærentzen3, Marianne Nordsmark2, Ole Steen Nielsen4, Jan Alsner5, Brita S Sørensen5.
Abstract
OBJECTIVE: Reverse transcription quantitative real-time polymerase chain reaction is efficient for quantification of gene expression, but the choice of reference genes is of paramount importance as it is essential for correct interpretation of data. This is complicated by the fact that the materials often available are routinely collected formalin-fixed, paraffin-embedded (FFPE) samples in which the mRNA is known to be highly degraded. The purpose of this study was to investigate 22 potential reference genes in sarcoma FFPE samples and to study the variation in expression level within different samples taken from the same tumor and between different histologic types.Entities:
Year: 2014 PMID: 25500077 PMCID: PMC4311021 DOI: 10.1016/j.tranon.2014.09.012
Source DB: PubMed Journal: Transl Oncol ISSN: 1936-5233 Impact factor: 4.243
Sample Characteristics
| Patient | Histology | Time | Age | Samples | No. of Genes | % Tumor | % Necrosis |
|---|---|---|---|---|---|---|---|
| (No.) | (year of biopsy) | (No.) | not detected | ||||
| 1 | Ewing | 1999 | 24 | 2 | 0/0 | 90/90 | 0/0 |
| 2 | Fibrosarcoma | 1994 | 36 | 1 | 0 | 100 | 0 |
| 3 | Leiomyosarcoma | 1995 | 66 | 3 | 0/0/0 | 100/100/100 | 0/0/0 |
| 4 | Leiomyosarcoma | 1994 | 53 | 3 | 0/1/6 | 100/90/80 | 0/0/20 |
| 5 | Liposarcoma | 1999 | 69 | 3 | 0/0/0 | 30/30/0 | 60/60/100 |
| 6 | Liposarcoma | 2001 | 54 | 3 | 0/0/0 | 80/80/100 | 0/0/0 |
| 7 | Liposarcoma | 1993 | 80 | 3 | 0/0/0 | 100/20/30 | 0/80/70 |
| 8 | Liposarcoma | 1994 | 45 | 3 | 8/0/8 | 20/100/100 | 80/0/0 |
| 9 | Liposarcoma | 2000 | 64 | 3 | 0/0/0 | 0/0/0 | 0/0/0 |
| 10 | Liposarcoma | 2001 | 56 | 3 | 0/0/0 | 50/50/60 | 0/0/30 |
| 11 | Liposarcoma | 1994 | 77 | 3 | 0/1/0 | 90/80/40 | 10/20/60 |
| 12 | Liposarcoma | 1995 | 77 | 3 | 0/0/0 | 100/90/100 | 0/10/0 |
| 13 | PUS | 1993 | 74 | 3 | 19/0/1 | 0/0/0 | 100/80/0 |
| 14 | PUS | 1998 | 64 | 3 | 0/0/0 | 20/20/60 | 0/0/0 |
| 15 | PUS | 1993 | 73 | 3 | 0/0/0 | 100/100/60 | 0/0/0 |
| 16 | PUS | 1993 | 53 | 1 | 0 | 90 | 10 |
| 17 | PUS | 1994 | 76 | 4 | 0/0/0/0 | 85/70/70/70 | 10/0/20/10 |
| 18 | PUS | 1993 | 67 | 3 | 0/0/0 | 75/30/40 | 30/60/60 |
| 19 | PUS | 1993 | 64 | 6 | 6/0/0/0/0/0 | 100/50/100/95/100 | 0/50/0/0/0 |
| 20 | PUS | 1993 | 43 | 3 | 0/0/0 | 80/60/0 | 20/40/0 |
| 21 | PUS | 1993 | 87 | 2 | 0/1 | 60/40 | 30/50 |
| 22 | PUS | 1993 | 63 | 3 | 0/0/0 | 100/100/90 | 0/0/10 |
| 23 | PUS | 1993 | 81 | 3 | 15/6/17 | 10/10/10 | 90/90/90 |
| 23 | Osteosarcoma | 1994 | 54 | 2 | 0/0 | 80/90 | 0/0 |
| 24 | MPNST | 2000 | 51 | 3 | 0/0/8 | 90/100/0 | 10/0/0 |
| 25 | MPNST | 1998 | 37 | 3 | 0/0/0 | 90/80/20 | 0/10/80 |
| 26 | Synovial sarcoma | 1998 | 50 | 3 | 0/0/0 | 95/60/60 | 5/0/10 |
| 27 | Synovial sarcoma | 1991 | 45 | 3 | 0/0/0 | 100/60/70 | 0/40/30 |
| 29 | Synovial sarcoma | 1997 | 33 | 1 | 9 | 90 |
The following genes were not included in the analysis: HMBS, HPRT1, TFRC, and PSMC4.
Summary of the Candidate Reference Genes and Function
| Gene Symbol | Gene Name | Gene Function | Assay ID | Amplicon |
|---|---|---|---|---|
| Actin, βActin, β | Structural protein (cytoskeletal) | Hs01060665_g1 | 63 | |
| ARP3 actin-related protin 3 homolog | Major constituent of the ARP2/3 complex | Hs01029161_m1 | 72 | |
| β-2-microglobulin | Beta-chain of major histocompatibility complex class I molecules | Hs00984230_m1 | 80 | |
| Calmodulin 2 | Calcium-binding messenger protein | 72 | ||
| Coiled-coil-helix domain containing 1 | Nuclear protein | Hs00415054_m1 | 79 | |
| Glyceraldehyde-3-phosphate dehydrogenase | Glycolysis | Hs02758991_g1 | 97 | |
| Glucuronidase, β | Degradation of dermatan and keratan sulfates | Part no 4333767F | 81 | |
| Hydroxymethylbilane synthase | Heme synthesis, porphyrin metabolism | Hs00609293_g1 | 62 | |
| Hypozanthine phosphoribosyl transferase | Purine salvage | Part no 4333768T | 100 | |
| Importin 8 | Nuclear protein import | Hs00183533_m1 | 71 | |
| Mitochondrial ribosomal protein L19 | Component of the large ribosomal subunit | Hs00608519_m1 | 72 | |
| Nedd4 family interacting protein 1 | Integral Golgi membrane proteins | Hs00228968_m1 | 67 | |
| RNA polymerase II | Catalyzes the RNA synthesis | Hs01108291_m1 | 86 | |
| Peptidylpropyl isomerase A | Part no. 4333763F | 98 | ||
| Proteasome 26S subunit | ATP-dependent degradation of ubiquitinated protien | Hs00197826_m1 | 83 | |
| Pumilio homolog 1 | translational regulation of mRNA | Hs00472881_m1 | 77 | |
| Ribosomal protein L37a | Protein synthesis | 65 | ||
| Ribosomal protein, large, P0 | Structural protein of ribosomes | Hs00420895_gH | 76 | |
| Hs03928990_g1 | 61 | |||
| Splicing factor 3a, subunit 1 | pre-mRNA splicing | Hs01066327_m1 | 64 | |
| TATA box binding protin | RNA prolymerase II transcription factor | Hs00427621_m1 | 65 | |
| Transferrin receptor | Uptake of iron | Hs00951083_m1 | 66 |
Supplied by ABI.
Primer (forward/reverse) GAGCGAGCTGAGTGGTTGTG/AGTCAGTTGGTCAGCCATGCT probe: TCGCGTCTCGGAAACCGGAGC, supplied by DNA Technology.
Primer (forward/reverse) TGTGGTTCCTGCATGAAGACA/GTGACAGCGGAAGTGGTATTGTAC probe:TGGCTGGCGGTGCCTGGA, supplied by DNA Technology.
Ranking of the Genes by Tissue Type and Algorithm
| Gene Symbol | All Tissue Samples | Liposarcoma and MFH Together | Liposarcoma | MFH | Overall | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M Value | Rank | S Score | Rank | M Value | Rank | S Score | Rank | M Value | Rank | S Score | Rank | M Value | Rank | S Score | Rank | Rank | |
| 0.89 | 7 | 0.39 | 5 | 0.89 | 11 | 0.22 | 11 | 0.86 | 13 | 0.49 | 12 | 1 | 0.36 | 7 | 8 | ||
| 1.41 | 14 | 0.55 | 14 | 0.99 | 14 | 0.18 | 8 | 0.86 | 12 | 0.43 | 10 | 0.76 | 10 | 0.40 | 11 | 12 | |
| 1.41 | 15 | 0.68 | 18 | 1.22 | 16 | 0.22 | 13 | 1.24 | 17 | 0.81 | 18 | 1.11 | 19 | 0.61 | 19 | 17 | |
| 3 | 0.25 | 1 | 0.79 | 5 | 0.13 | 3 | 0.67 | 6 | 0.38 | 6 | 0.71 | 9 | 0.40 | 10 | 4 | ||
| 0.83 | 5 | 0.41 | 7 | 0.80 | 6 | 0.16 | 5 | 0.63 | 5 | 0.40 | 8 | 0.72 | 8 | 0.34 | 4 | 6 | |
| 1.61 | 17 | 0.61 | 16 | 1.50 | 18 | 0.29 | 17 | 1.58 | 18 | 0.95 | 19 | 1.07 | 17 | 0.48 | 14 | 18 | |
| 1.70 | 18 | 0.49 | 11 | 0.88 | 10 | 0.19 | 10 | 2.14 | 19 | 0.76 | 17 | 0.95 | 15 | 0.54 | 16 | 14 | |
| 4 | 0.49 | 12 | 4 | 0.11 | 1 | 0.61 | 4 | 0.25 | 2 | 0.85 | 12 | 0.50 | 15 | 7 | |||
| 1 | 0.34 | 4 | 0.81 | 7 | 0.14 | 4 | 1 | 0.36 | 4 | 3 | 0.29 | 2 | 1 | ||||
| 1.28 | 13 | 0.44 | 8 | 1.36 | 17 | 0.31 | 18 | 1.20 | 16 | 0.65 | 16 | 0.69 | 7 | 3 | 13 | ||
| 1.18 | 11 | 0.49 | 10 | 0.87 | 9 | 0.13 | 2 | 0.82 | 11 | 0.47 | 11 | 0.91 | 14 | 0.44 | 13 | 11 | |
| 0.86 | 6 | 2 | 1 | 0.17 | 7 | 0.73 | 8 | 7 | 0.64 | 4 | 0.36 | 6 | 3 | ||||
| 1.55 | 16 | 0.60 | 15 | 0.94 | 12 | 0.22 | 12 | 0.93 | 14 | 0.57 | 15 | 0.98 | 16 | 0.57 | 17 | 15 | |
| 1.08 | 9 | 0.49 | 13 | 0.97 | 13 | 0.28 | 15 | 2 | 5 | 0.78 | 11 | 0.38 | 9 | 10 | |||
| 1.00 | 8 | 0.46 | 9 | 0.87 | 8 | 6 | 0.79 | 10 | 0.42 | 9 | 0.88 | 13 | 0.43 | 12 | 9 | ||
| 1.21 | 12 | 0.64 | 17 | 1.15 | 15 | 0.28 | 16 | 1.00 | 15 | 0.56 | 14 | 1.07 | 18 | 0.61 | 18 | 16 | |
| 1.16 | 10 | 0.39 | 6 | 2 | 0.18 | 9 | 3 | 0.23 | 1 | 2 | 1 | 2 | |||||
| 2 | 3 | 3 | 14 | 0.71 | 7 | 0.35 | 3 | 0.66 | 6 | 0.37 | 8 | 5 | |||||
The bold and underlined values are the recommended reference genes by the two different algorithms GeNorm and NormFinder when analyzing all tissue samples, liposarcoma and PUS together, and liposarcoma and PUS separately. From these results, an overall ranking was determined, and the three best ranking genes were selected as reference genes.
When considering the total rank of the different types analyzed, these 3 genes have the lowest score.
Figure 1∆Cq value for the three most stably expressed genes for each patient. The ∆Cq values were normalized to the geometric mean of the same three genes. The patient numbers are represented at the y-axis. The histologic type for patient number 1 was Ewing sarcoma; for patient number 2, fibrosarcoma; for patient numbers 3 to 4, leiomyosarcoma; for patient numbers 5 to 12, liposarcoma; for patient numbers 13 to 23, PUS; for patient number 24, osteosarcoma; for patient numbers 25 and 26, MPNST; and for patient numbers 27 to 29, synovial sarcoma. Four patients were not included as explained in Material and Methods.
Supplementary Figure 1The figure shows the ∆Cq value for each patient against sample number. Each line represents one patient, according to the investigated genes and histologic type of the patients. This is therefore representing the variation within each patient with different tissue samples and the variation between each patient according to the histologic type.
Supplementary Figure 2Bland-Altman plot of difference versus average, comparing the ∆Cq value in the highest and lowest ∆Cq value for each patient. The horizontal lines indicate the mean difference and 95% CI.
Figure 2Median centered ∆Cq values of the 22 studied reference genes, normalized to the three highest-ranking reference genes. All histologic types are represented in this figure. The number of tissue samples for each gene is 64. The y-axis represents each gene analyzed.
Figure 3The top figure shows the Cq value for the most stably expressed genes, with the slope of the line representing the degradation of the RNA/year. The bottom figure shows the ∆Cq value for the most stably expressed genes normalized to the geometric mean of the same three genes according to the age for the FFPE tissue blocks. The y-axis represents the year of diagnosis.